Effect of persistence with drug therapy on the risk of myocardial re-infarction

P and T

Volumn 33, Issue 5, 2008, Pages

  Shaya, Fadia T ^a   Gu, Anna ^b   Yan, Xia ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b ANALYSIS GROUP   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART DISEASE; HEART REINFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOME ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

EID: 45349083792     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636.
2. American Heart Association. Heart disease and stroke statistics, 2004 update. Dallas, Tex.
3. van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force of the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;(24):28-66.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
5. McCormick D, Gurwitz JH, Lessard D, et al. Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: Missed opportunities for prevention? Arch Intern Med 1999;159(6):561-567.
6. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-186.
7. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
8. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
9. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: Findings for five large cohorts of young adult and middle-aged men and women. JAMA 1999;282:2012-2018.
10. Kaiser Commission on Medicaid and the Uninsured. Medicaid Prescription Drug Spending and Use. Washington, DC: Henry J. Kaiser Foundations; 2004.
11. Shaya FT, El Khoury AC, Mullins CD, et al. Drug therapy persistence and stroke recurrence. Am J Manag Care 2006;12:313-319.
12. Brener SJ, Ellis SG, Sapp SK, et al. Predictors of death and reinfarction at 30 days after primary angioplasty: The GUSTO IIb and RAPPORT Trials. Am Heart J 2000;139(3):476-481.
13. De Luca G, Ernst N, van't Hof AWJ, et al. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J 2006;151:1256-1259.
14. van der Elst ME, Bouvy ML, de Blaev CJ, et al. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: A retrospective analysis. Clin Ther 2005;27(11):1806-1814.
15. Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
16. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham study. Ann Intern Med 1991;115:687-693.